Analysis of proton pump inhibitor usage in 129 hospitals across 9 cities in China from 2018 to 2022
Objective To analyze the usage and trends of proton pump inhibitors(PPI)in 129 hospitals across 9 cities in China from 2018 to 2022,providing reference for the scientific management and rational clinical use of proton pump inhibitors in hospitals.Methods Prescription data involving PPI usage(including outpatient prescriptions and inpatient orders)were randomly selected from hospitals participating in the China Pharmaceutical Association's Prescription Analysis Project.Sales amount,sales quantity,defined daily doses(DDDs),defined daily cost(DDC),ratio of sales amount ranking(B)to DDDs ranking(A),along with the annual average growth rate of PPIs were calculated to analyze their clinical application.Results A total of 12 103 464 PPI prescription/medical order data were extracted,involving 129 hospitals in 9 cities.The number of patients using PPIs increased with age.From 2018 to 2022,esomeprazole injection ranked first in sales amount,and rabeprazole ranked first in oral form sales amount,while pantoprazole led in both injectable and oral sales quantity.Omeprazole led in DDDs for injectables,while rabeprazole led in oral DDDs.Only rabeprazole and eprazole have a DDC greater than 100 yuan for injectable formulations,while other proton pump inhibitors have a DDC of 20-60 yuan.For oral PPIs,only eprazole had a DDC greater than 10 yuan,while all other PPIs had a DDC less than 10 yuan.The B/A ratio of injectable lansoprazole,rabeprazole,and eprazole was equal to 1,while the B/A ratio of esomeprazole was less than 1.Conversely,the B/A ratio of injectablenomeprazole and pantoprazole was greater than 1.Oral formulations of rabeprazole,esomeprazole,and eprazole had a B/A ratio of less than 1,while omeprazole,lansoprazole,and pantoprazole had a B/A ratio greater than 1.Conclusion In clinical practice,omeprazole is more commonly used in injectable form,while rabeprazole is more commonly used in oral form.Lansoprazole,rabeprazole,and eprazole show synchronous frequency and cost usage patterns among injectables.
NETL
NSTL
万方数据
